1. Home
  2. PINC vs NRIX Comparison

PINC vs NRIX Comparison

Compare PINC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PINC
  • NRIX
  • Stock Information
  • Founded
  • PINC 2013
  • NRIX 2009
  • Country
  • PINC United States
  • NRIX United States
  • Employees
  • PINC N/A
  • NRIX N/A
  • Industry
  • PINC Other Consumer Services
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PINC Consumer Discretionary
  • NRIX Health Care
  • Exchange
  • PINC Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • PINC 1.6B
  • NRIX 1.4B
  • IPO Year
  • PINC 2013
  • NRIX 2020
  • Fundamental
  • Price
  • PINC $18.61
  • NRIX $16.87
  • Analyst Decision
  • PINC Hold
  • NRIX Strong Buy
  • Analyst Count
  • PINC 7
  • NRIX 16
  • Target Price
  • PINC $20.42
  • NRIX $31.75
  • AVG Volume (30 Days)
  • PINC 1.3M
  • NRIX 658.9K
  • Earning Date
  • PINC 02-04-2025
  • NRIX 04-09-2025
  • Dividend Yield
  • PINC 4.51%
  • NRIX N/A
  • EPS Growth
  • PINC N/A
  • NRIX N/A
  • EPS
  • PINC N/A
  • NRIX N/A
  • Revenue
  • PINC $1,285,872,000.00
  • NRIX $54,549,000.00
  • Revenue This Year
  • PINC N/A
  • NRIX $3.28
  • Revenue Next Year
  • PINC N/A
  • NRIX $6.73
  • P/E Ratio
  • PINC $49.57
  • NRIX N/A
  • Revenue Growth
  • PINC 6.14
  • NRIX N/A
  • 52 Week Low
  • PINC $17.70
  • NRIX $10.17
  • 52 Week High
  • PINC $23.56
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • PINC 35.46
  • NRIX 35.92
  • Support Level
  • PINC $17.70
  • NRIX $16.56
  • Resistance Level
  • PINC $19.03
  • NRIX $18.07
  • Average True Range (ATR)
  • PINC 0.73
  • NRIX 0.91
  • MACD
  • PINC -0.07
  • NRIX -0.13
  • Stochastic Oscillator
  • PINC 18.21
  • NRIX 9.95

About PINC Premier Inc.

Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Share on Social Networks: